Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma

Experimental Biology and Medicine

Volumn 241, Issue 9, 2016, Pages 1007-1013

  Knapp, Christopher M ^a   He, Jia ^a   Lister, John ^b   Whitehead, Kathryn A ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b ALLEGHENY HEALTH NETWORK   (United States)

Author keywords

mantle cell lymphoma; Mcl 1; nanomedicine; nanoparticles; siRNA

Indexed keywords

GENE THERAPY AGENT; LIPID; LIPIDOID 306 O 13; LIPIDOID NANOPARTICLE; MESSENGER RNA; NANOPARTICLE; PROTEIN MCL 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MCL1 PROTEIN, HUMAN;

ADDITION REACTION; APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; WESTERN BLOTTING; CHEMISTRY; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; GENE SILENCING; HUMANS; LYMPHOMA, MANTLE-CELL; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NANOPARTICLES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84971635810     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370216640944     Document Type: Article

References (48)

1. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin K. SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1975_2011/ (2014, accessed 18 April 2014)
2. S.KrajewskiS.BodrugM.KrajewskaA.ShabaikR.GascoyneK.BereanJ.C.Reed. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol1995; 146: 1309–19.
3. J.D.KhouryL.J.MedeirosG.Z.RassidakisT.J.McDonnellL.V.AbruzzoR.Lai. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol2003; 199: 90–7.
4. C.TouzeauC.DoussetL.BodetP.Gomez-BougieS.BonnaudA.MoreauP.MoreauC.Pellat-DeceunynkM.AmiotS.L.Gouill. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Clin Cancer Res2011; 17: 5973–81.
5. L.W.ThomasC.LamS.W.Edwards. Mcl-1; the molecular regulation of protein function. FEBS Lett2010; 584: 2981–9.
6. S.Wuillème-ToumiN.RobillardP.GomezP.MoreauS.Le GouillH.Avet-LoiseauJ.-L.HarousseauM.AmiotR.Bataille. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia2005; 19: 1248–52.
7. S.P.GlaserE.F.LeeE.TrounsonP.BouilletA.WeiW.D.FairlieD.J.IzonJ.ZuberA.R.RappaportM.J.HeroldW.S.AlexanderS.W.LoweL.RobbA.Strasser. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev2012; 26: 120–5.
8. R.BeroukhimC.H.MermelD.PorterG.WeiS.RaychaudhuriJ.DonovanJ.BarretinaJ.S.BoehmJ.DobsonM.UrashimaK.T.Mc HenryR.M.PinchbackA.H.LigonY.-J.ChoL.HaeryH.GreulichM.ReichW.WincklerM.S.LawrenceB.A.WeirK.E.TanakaD.Y.ChiangA.J.BassA.LooC.HoffmanJ.PrensnerT.LiefeldQ.GaoD.YeciesS.SignorettiE.MaherF.J.KayeH.SasakiJ.E.TepperJ.A.FletcherJ.TaberneroJ.BaselgaM.-S.TsaoF.DeMichelisM.A.RubinP.A.JanneM.J.DalyC.NuceraR.L.LevineB.L.EbertS.GabrielA.K.RustgiC.R.AntonescuM.LadanyiA.LetaiL.A.GarrawayM.LodaD.G.BeerL.D.TrueA.OkamotoS.L.PomeroyS.SingerT.R.GolubE.S.LanderG.GetzW.R.SellersM.Meyerson. The landscape of somatic copy-number alteration across human cancers. Nature2010; 463: 899–905.
9. A.J.SouersJ.D.LeversonE.R.BoghaertS.L.AcklerN.D.CatronJ.ChenB.D.DaytonH.DingS.H.EnschedeW.J.FairbrotherD.C.S.HuangS.G.HymowitzS.JinS.L.KhawP.J.KovarL.T.LamJ.LeeH.L.MaeckerK.C.MarshK.D.MasonM.J.MittenP.M.NimmerA.OleksijewC.H.ParkC.-M.ParkD.C.PhillipsA.W.RobertsD.SampathJ.F.SeymourM.L.SmithG.M.SullivanS.K.TahirC.TseM.D.WendtY.XiaoJ.C.XueH.ZhangR.A.HumerickhouseS.H.RosenbergS.W.Elmore. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med2013; 19: 202–8.
10. G.S.ChoudharyS.Al-harbiS.MazumderB.T.HillM.R.SmithJ.BodoE.D.HsiA.Almasan. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis2015; 6: e1593–e1593.
11. S.Al-HarbiB.T.HillS.MazumderK.SinghJ.DeVecchioG.ChoudharyL.A.RybickiM.KalaycioJ.P.MaciejewskiJ.A.HoughtonA.Almasan. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood2011; 118: 3579–90.
12. J.D.LeversonH.ZhangJ.ChenS.K.TahirD.C.PhillipsJ.XueP.NimmerS.JinM.SmithY.XiaoP.KovarA.TanakaM.BrunckoG.S.SheppardL.WangS.GierkeL.KategayaD.J.AndersonC.WongJ.Eastham-AndersonM.J.C.LudlamD.SampathW.J.FairbrotherI.WertzS.H.RosenbergC.TseS.W.ElmoreA.J.Souers. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis2015; 6: e1590–e1590.
13. F.AbulwerdiC.LiaoM.LiuA.S.AzmiA.AboukameelA.S.A.MadyT.GulappaT.CierpickiS.OwensT.ZhangD.SunJ.A.StuckeyR.M.MohammadZ.Nikolovska-Coleska. A novel small-molecule inhibitor of Mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther2014; 13: 565–75.
14. E.CampoS.Rule. Mantle cell lymphoma: evolving management strategies. Blood2015; 125: 48–55.
15. I.F.KhouriJ.RomagueraH.KantarjianJ.L.PalmerW.C.PughM.KorblingF.HagemeisterB.SamuelsA.RodriguezS.GiraltA.YounesD.PrzepiorkaD.ClaxtonF.CabanillasR.Champlin. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol1998; 16: 3803–9.
16. B.CoiffierC.ThieblemontE.V.D.NesteG.LepeuI.PlantierS.CastaigneS.LefortG.MaritM.MacroC.SebbanK.BelhadjD.BordessouleC.FerméH.Tilly. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood2010; 116: 2040–5.
17. C.BognerT.DechowI.RingshausenM.WagnerM.OelsnerG.LutznyT.LichtC.PeschelI.PastanR.J.KreitmanT.Decker. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Br J Haematol2010; 148: 99–109.
18. A.MüllerC.ZangC.ChumduriB.DörkenP.T.DanielC.W.Scholz. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Int J Cancer2013; 133: 1813–24.
19. S.-R.A.HussainC.M.CheneyA.J.JohnsonT.S.LinM.R.GreverM.A.CaligiuriD.M.LucasJ.C.Byrd. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res2007; 13: 2144–50.
20. N.P.ShirsathS.M.ManoharK.S.Joshi. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. Mol Cancer2012; 11: 77–77.
21. K.A.WhiteheadJ.R.DorkinA.J.VegasP.H.ChangO.VeisehJ.MatthewsO.S.FentonY.ZhangK.T.OlejnikV.YesilyurtD.ChenS.BarrosB.KlebanovT.NovobrantsevaR.LangerD.G.Anderson. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun2014; 5: 4277–4277.
22. R.L.BallC.M.KnappK.A.Whitehead. Lipidoid nanoparticles for siRNA delivery to the intestinal epithelium: in vitro investigations in a Caco-2 model. PLoS ONE2015; 10: e0133154–e0133154.
23. C.Akgul. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci CMLS2009; 66: 1326–36.
24. M.C.Palanca-WesselsA.J.ConvertineR.Cutler-StromG.C.BoothF.LeeG.Y.BerguigP.S.StaytonO.W.Press. Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol Ther2011; 19: 1529–37.
25. S.M.FrancisC.A.TaylorT.TangZ.LiuQ.ZhengR.DonderoJ.E.Thompson. SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide. Mol Ther2014; 22: 1643–52.
26. J.ZhouK.TiemannP.ChomchanJ.AlluinP.SwiderskiJ.BurnettX.ZhangS.FormanR.ChenJ.Rossi. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res2013; 41: 4266–83.
27. A.ZamoG.OttT.KatzenbergerP.AdamC.ParoliniA.ScarpaM.LestaniF.MenestrinaM.Chilosi. Establishment of the MAVER-1 cell line, a model for leukemic and aggressive mantle cell lymphoma. Haematologica2006; 91: 40–7.
28. L.H.Sehn. A decade of R-CHOP. Blood2010; 116: 2000–1.
29. S.M.AukemaR.SiebertE.SchuuringImhoff GW vanH.C.Kluin-NelemansE.-J.BoermaP.M.Kluin. Double-hit B-cell lymphomas. Blood2011; 117: 2319–31.
30. H.J.JeonC.W.KimT.YoshinoT.Akagi. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol1998; 102: 1323–6.
31. C.M.KnappK.A.Whitehead. In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma. Expert Opin Drug Deliv2014; 11: 1923–37.
32. T.LammersF.KiesslingW.E.HenninkG.Storm. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Contr Release2012; 161: 175–87.
33. K.LoomisB.SmithY.FengH.GargA.YavlovichR.Campbell-MassaD.S.DimitrovR.BlumenthalX.XiaoA.Puri. Specific targeting to B Cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Exp Mol Pathol2010; 88: 238–49.
34. J.M.TuscanoS.M.MartinY.MaW.ZamboniR.T.O’Donnell. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-hodgkin’s lymphoma xenograft mouse model. Clin Cancer Res2010; 16: 2760–8.
35. W.C.ChenG.C.CompletoD.S.SigalP.R.CrockerA.SavenJ.C.Paulson. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood2010; 115: 4778–86.
36. A.M.ChenM.ZhangD.WeiD.StueberO.TaratulaT.MinkoH.He. Co-delivery of Doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small2009; 5: 2673–7.
37. W.ChenY.YuanD.ChengJ.ChenL.WangX.Shuai. Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy. Small Weinh Bergstr Ger2014; 10: 2678–87.
38. C.LiuF.LiuL.FengM.LiJ.ZhangN.Zhang. The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials2013; 34: 2547–64.
39. S.SunM.WangS.A.KnuppY.Soto-FelicianoX.HuD.L.KaplanR.LangerD.G.AndersonQ.Xu. Combinatorial library of lipidoids for in vitro DNA delivery. Bioconjug Chem2012; 23: 135–40.
40. S.SunM.WangK.A.AlbertiA.ChoyQ.Xu. DOPE facilitates quaternized lipidoids (QLDs) for in vitro DNA delivery. Nanomed Nanotechnol Biol Med2013; 9: 849–54.
41. M.WangS.SunK.A.AlbertiQ.Xu. A combinatorial library of unsaturated lipidoids for efficient intracellular gene delivery. ACS Synth Biol2012; 1: 403–7.
42. M.WangK.AlbertiS.SunC.L.ArellanoQ.Xu. Combinatorially designed lipid-like nanoparticles for intracellular delivery of cytotoxic protein for cancer therapy. Angew Chem Int Ed2014; 53: 2893–8.
43. S.JiangA.A.EltoukhyK.T.LoveR.LangerD.G.Anderson. Lipidoid-coated iron oxide nanoparticles for efficient DNA and siRNA delivery. Nano Lett2013; 13: 1059–64.
44. J.MichelsF.ObristI.VitaleD.LissaP.GarciaP.Behnam-MotlaghK.KohnoG.S.WuC.BrennerM.CastedoG.Kroemer. MCL-1 dependency of cisplatin-resistant cancer cells. Biochem Pharmacol2014; 92: 55–61.
45. L.SongD.CoppolaS.LivingstonW.D.CressE.B.Haura. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther2005; 4: 267–76.
46. M.F.Van DelftA.H.WeiK.D.MasonC.J.VandenbergL.ChenP.E.CzabotarS.N.WillisC.L.ScottC.L.DayS.CoryJ.M.AdamsA.W.RobertsD.C.S.Huang. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell2006; 10: 389–99.
47. Pham L, Zhang L, Tao W, Zhao D, Zhang H, Xie J, Wang J, Nomie K, Wang M. Developing novel therapeutic strategies to overcome ibrutinib resistance in mantle cell lymphoma. Orlando, FL, https://ash.confex.com/ash/2015/webprogram/Paper85213.html (2015, accessed 9 March 2016)
48. G.WeiD.TwomeyJ.LambK.SchlisJ.AgarwalR.W.StamJ.T.OpfermanS.E.SallanM.L.den BoerR.PietersT.R.GolubS.A.Armstrong. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell2006; 10: 331–42.